Summit Therapeutics (SMMT) Faces An FDA Reset, Is The Downside Already Priced In?
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
Why Is Summit Therapeutics (SMMT) Facing An FDA Setback For Ivonescimab?
SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter
Summit Therapeutics tumbles 13% after FDA rejects lung cancer drug application
Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
Summit Therapeutics Says FDA Rejects Ivonescimab Application for Lung Cancer Treatment; Shares Fall Pre-Bell
Evercore ISI Group Maintains Outperform on Summit Therapeutics, Lowers Price Target to $33
SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test
FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?
Summit Therapeutics (SMMT) Stock Looks Richly Priced On Its 7x Run
Summit Therapeutics Q3 Adj. EPS $(0.20) Beats $(0.28) Estimate
Summit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI Deal
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.